All Resources

Private Drug Coverage • November 25, 2022

Cost Drivers: Analysis of Private Drug Plans in Canada 2022

Learn more|View

Access to Medicine • November 17, 2022

Innovative Agreements Framework

Learn more|View

Access to Medicine • November 10, 2022

Canadian Drug Access Pathway

…Canadian patients to get access to a drug in the public plan, whereas those in the private plan get access to a drug in less than one year (226 days)….

Learn more|View

Patented Medicine Prices Review Board (PMPRB) • November 09, 2022

Letter to The Honourable Jean-Yves Duclos, P.C., M.P.

Learn more|View

Patented Medicine Prices Review Board (PMPRB) • November 09, 2022

Letter to The Hon. Chrystia Freeland, P.C., M.P.

Learn more|View

Patented Medicine Prices Review Board (PMPRB) • November 09, 2022

Letter to The Honourable Mary Ng, P.C., M.P.

Learn more|View

Patented Medicine Prices Review Board (PMPRB) • November 09, 2022

Ministerial PMPRB Guideline Letter to The Hon. François-Philippe Champagne, P.C., M.P.

Learn more|View

Economic Impact • October 07, 2022

Pre-Budget Consultations in Advance of the 2023 Budget

Learn more|View

Access to Medicine • July 06, 2022

Developing a Pan-Canadian Genomics Strategy: Innovative Medicines Canada Response

Learn more|View

Access to Medicine • June 28, 2022

Search for Specific Brand Name Drug Negotiations Status with the pCPA

Learn more|View

Access to Medicine • June 28, 2022

pCPA overview of the Negotiation Process

Learn more|View

April 28, 2022

Reflections on a Potential Pan-Canadian Drug Formulary: Medicines Industry Response to CADTH Consultation

Learn more|View